Adalimumab — Discount Pricing

Other medications in Digestive Health

• Alosetron
• Bisacodyl
• Budesonide (Crohn)
• Certolizumab
• Cholestyramine (GI)
• Dexlansoprazole
• Docusate
• Eluxadoline

About Adalimumab

Adalimumab is a powerful biologic medication prescribed for various chronic inflammatory conditions. While incredibly effective, its cost can be a significant concern. TheDrugClub is dedicated to helping our members access essential medications like adalimumab at more affordable prices, ensuring you can prioritize your health without financial strain.

What is Adalimumab and What Does It Treat?

Adalimumab is a prescription medication belonging to a class of drugs called TNF-alpha blockers. It is an immunosuppressant used to treat a range of chronic autoimmune and inflammatory conditions where the body's immune system mistakenly attacks its own tissues. Common conditions treated with adalimumab include:

• Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting joints.
• Psoriatic Arthritis (PsA): A form of arthritis that affects some people with psoriasis.
• Ankylosing Spondylitis (AS): A form of arthritis that primarily affects the spine.
• Crohn's Disease (CD): An inflammatory bowel disease.
• Ulcerative Colitis (UC): Another inflammatory bowel disease.

*

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Adalimumab is approved for (FDA label)

Adalimumab-aacf is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: January 8, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Adalimumab (FDA label)

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue Adalimumab-aacf if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-aacf. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ) : Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products including Adalimumab-aacf are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-aacf if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease.

Source: FDA prescribing information (DailyMed). Set ID: 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915. SPL document ID: ed59e023-eb91-482f-a1fe-19a31c0906c2. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Adalimumab (FDA label)

Adalimumab-aacf is a clear and colorless to pale yellow solution available as: Pen (Adalimumab-aacf Pen) Injection: 40 mg/0.8 mL in a single-dose pen. Prefilled Syringe Injection: 40 mg/0.8 mL in a single-dose prefilled glass syringe. Single-Dose Institutional Use Vial Kit Injection: 40 mg/0.8 mL in a single-dose, glass vial kit for institutional use only. Injection: Single-dose prefilled pen (Adalimumab-aacf Pen): 40 mg/0.8 mL ( 3 ) Single-dose prefilled glass syringe: 40 mg/0.8 mL ( 3 ) Single dose glass vial kit for institutional use only: 40mg/0.8 mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915. SPL document ID: ed59e023-eb91-482f-a1fe-19a31c0906c2. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Adalimumab (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions ( 5.1 )] Malignancies [see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 )] Hepatitis B Virus Reactivation [see Warnings and Precautions ( 5.4 )] Neurologic Reactions [see Warnings and Precautions ( 5.5 )] Hematological Reactions [see Warnings and Precautions ( 5.6 )] Heart Failure [see Warnings and Precautions ( 5.8 )] Autoimmunity [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (>10%) are infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088- or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915. SPL document ID: ed59e023-eb91-482f-a1fe-19a31c0906c2. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.